{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:07:20Z","timestamp":1789085240913,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lana.2023.100636","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T18:33:56Z","timestamp":1701714836000},"page":"100636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-6203","authenticated-orcid":false,"given":"Arthur Robin","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexa","family":"Harpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-1517","authenticated-orcid":false,"given":"Nicole","family":"Aydinoglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2023.100636_bib1","series-title":"National Survey of substance abuse treatment services (N-SSATS), 2019","year":"2020"},{"key":"10.1016\/j.lana.2023.100636_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019\"","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J\u00a0Addict Dis"},{"key":"10.1016\/j.lana.2023.100636_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.lana.2023.100636_bib5","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.lana.2023.100636_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"8","key":"10.1016\/j.lana.2023.100636_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A\u00a0medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.lana.2023.100636_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/08897077.2020.1752351","article-title":"Opioid use disorder and the COVID 19 pandemic: a call to sustain regulatory easements and further expand access to treatment","volume":"41","author":"Green","year":"2020","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.lana.2023.100636_bib9","doi-asserted-by":"crossref","first-page":"E238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesizing evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"Lancet Public Health"},{"issue":"S2","key":"10.1016\/j.lana.2023.100636_bib10","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"key":"10.1016\/j.lana.2023.100636_bib11","series-title":"FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19","first-page":"5","author":"Substance Abuse and Mental Health Services Administration","year":"2020"},{"issue":"7","key":"10.1016\/j.lana.2023.100636_bib12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1080\/10826084.2022.2064509","article-title":"Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities","volume":"57","author":"Walters","year":"2022","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.lana.2023.100636_bib13","series-title":"National drug Abuse treatment clinical trials network","year":"2023"},{"key":"10.1016\/j.lana.2023.100636_bib14","series-title":"National quality forum (NQF): behavioral health 2016-2017: technical report","year":"2017"},{"issue":"2","key":"10.1016\/j.lana.2023.100636_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/02791072.2014.901587","article-title":"Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention","volume":"46","author":"White","year":"2014","journal-title":"J\u00a0Psychoact Drugs"},{"issue":"2-3","key":"10.1016\/j.lana.2023.100636_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","article-title":"Predictors of methadone treatment retention from a multi-site study: a survival analysis","volume":"117","author":"Kelly","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.lana.2023.100636_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.11.020","article-title":"Predictors of retention in methadone programs: a signal detection analysis","volume":"83","author":"Villafranca","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02287327","article-title":"Retention in publicly funded methadone maintenance treatment in two Western States","volume":"32","author":"Deck","year":"2005","journal-title":"J\u00a0Behav Health Serv Res"},{"issue":"3","key":"10.1016\/j.lana.2023.100636_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0376-8716(01)00171-5","article-title":"Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis","volume":"65","author":"Farr\u00e9","year":"2002","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.lana.2023.100636_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0376-8716(99)00088-5","article-title":"Retention and patient engagement models for different treatment modalities in DATOS","volume":"57","author":"Joe","year":"1999","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0376-8716(98)00047-7","article-title":"Staff attitudes and retention of patients in methadone maintenance programs","volume":"52","author":"Caplehorn","year":"1998","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1360-0443.1998.931516.x","article-title":"Pre- and in-treatment predictors of retention in methadone treatment using survival analysis","volume":"93","author":"Magura","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.lana.2023.100636_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drugalcdep.2004.08.011","article-title":"Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing","volume":"77","author":"Marsch","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lana.2023.100636_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: lowering the treatment thresholds","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.lana.2023.100636_bib25","article-title":"COVID 19 and the opioid epidemic: an analysis of clinical outcomes during COVID 19","volume":"16","author":"Ezie","year":"2022","journal-title":"Subst Abus"},{"issue":"12","key":"10.1016\/j.lana.2023.100636_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.lana.2023.100636_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine\u2013naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib28","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A\u00a0randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.lana.2023.100636_bib29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/add.12439","article-title":"Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial","volume":"109","author":"Holland","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.lana.2023.100636_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pnpbp.2010.12.002","article-title":"Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance","volume":"35","author":"Gerra","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.lana.2023.100636_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108276","article-title":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","volume":"123","author":"Figgatt","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"6","key":"10.1016\/j.lana.2023.100636_bib32","first-page":"516","article-title":"Reduction in Oregon's medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication","volume":"15","author":"McIlveen","year":"2021","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.lana.2023.100636_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108801","article-title":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis","volume":"141","author":"Hoffman","year":"2022","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.lana.2023.100636_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-022-04175-9","article-title":"Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine\/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province","volume":"22","author":"Sadek","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.lana.2023.100636_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"10.1016\/j.lana.2023.100636_bib36","first-page":"S323","article-title":"Large variation in measures used to assess outcomes of opioid dependence treatment: a systematic review of longitudinal observational studies","volume":"37","author":"Wiessing","year":"2018","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"10.1016\/j.lana.2023.100636_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsat.2004.06.001","article-title":"A\u00a0conceptual framework for drug treatment process and outcomes","volume":"27","author":"Simpson","year":"2004","journal-title":"J\u00a0Subst Abuse Treat"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:55:24Z","timestamp":1762642524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X23002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":37,"alternative-id":["S2667193X23002107"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2023.100636","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2023.100636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100636"}}